key: cord-0847420-5yzi7nil
authors: Alshukairi, Abeer N; El-Kafrawy, Sherif A; Dada, Ashraf; Yasir, Mohamed; Yamani, Amani H; Saeedi, Mohammed F; Aljohaney, Ahmed; AlJohani, Naif I; Bahaudden, Husam A; Alam, Intikhab; Gojobori, Takashi; Radovanovic, Aleksandar; Alandijany, Thamir A; Othman, Norah A.; Alsubhi, Tagreed L.; Hassan, Ahmed M; Tolah, Ahmed M; Al-Tawfiq, Jaffar A.; Zumla, Alimuddin; Azhar, Esam I
title: Re-infection with different SARS-CoV-2 clade and prolonged viral shedding in a patient with hematopoietic stem cell transplantation: SARS-CoV-2 Re-infection with different clade
date: 2021-07-18
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.07.036
sha: 4068a3cc0606c67a0ff7ebf6b819bbd335cfe837
doc_id: 847420
cord_uid: 5yzi7nil

Immunocompromised patients who have a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection pose many clinical and public health challenges. We describe the case of a hematopoietic stem cell transplantation patient with lymphoma who had a protracted illness requiring three consecutive hospital admissions. Whole genome sequencing confirmed two different SARS-CoV-2 clades. Clinical management issues and the unanswered questions arising from this case are discussed.

She improved clinically and was discharged home on day-7 post admission. The patient did 76 not receive Remdesivir since it was not available in our hospital during this period. She did 77 not receive steroids during this admission. 78

Second hospital admission: On day-19 post first admission, she was re-admitted to 79 hospital with fever, cough and dyspnea. Her oxygen saturation was 96% at room air and the 80 Chest X ray showed bilateral lung infiltrates. A nasopharyngeal swab PCR was positive for 81 SARS-CoV-2, Ct value 13. Chest CT scan showed diffuse bilateral ground glass opacities. 82

She received steroids, meropenem, and intravenous immunoglobulin (IVIG). She received 83 methylprednisolone 1mg/kg daily for 3 days followed by 0.5mg/kg daily for days two weeks 84 after her admission. SARS-CoV-2 serology was negative by both ELISA and 85 microneutralization antibody test (MNT) on day-40. She was discharged after three weeks of 86 hospitalization and managed in the outpatient setting for presumed cryptogenic organizing 87 pneumonia. She received 40 mg of prednisolone daily for 10 days followed by tapering 88 doses of prednisolone over one month. Then she received 30 mg of prednisolone daily for 89 three weeks followed by tapering doses of prednisolone over another month.. Her fever 90 improved but she had persistent exertional dyspnea. The patient re-presented with fever 91 and feeling unwell to the ER on day-114. A nasopharyngeal swab PCR was positive for 92 SARS-CoV-2, (Ct=17). She was prescribed a 7-day course of ciprofloxacin for pneumonia 93 and sent home. the utilization of three approaches to analyze the data in order to confirm the case as a re-168 infection. A real concern of this case is that she is a potential infection reservoir and an 

Reinfection with different clades of SARS-CoV-2 does occur in immunocompromised 196 patients and proactive screening for different clades of SARS-CoV-2 is required. Since WGS 197 is not yet routinely performed in most points of COVID-19 care, it is likely that the numbers 198 of cases of reinfection with different clades of SARS-CoV-2 is probably being 199 underestimated. More systematic studies with whole genome sequencing of all possible 200 cases of SARS-CoV-2 reinfection

WHO. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: 249

Persistence and Evolution of SARS-CoV-2 in 251 an Immunocompromised Host

Prolonged Severe Acute Respiratory 254

Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with 258

Defining the features and duration of antibody 260 responses to SARS-CoV-2 infection associated with disease severity and outcome

Convalescent plasma therapy for B-cell-263 depleted patients with protracted COVID-19

COVID-19 vaccine-readiness for anti-CD20-265 depleting therapy in autoimmune diseases

infectiousness among three immunocompromised patients: from prolonged viral 268 shedding to SARS-CoV-2 superinfection

SARS-CoV-2 evolution during treatment of 270 chronic infection

Sir Zumla is co-Principal Investigator of the Pan African-European Network on Emerging and 230Re-Emerging Infections (PANDORA-ID-NET-https://www.pandora-id.net/) funded by the

All authors declare no conflict of interest. 228